Clariane (CLARI) Stock Overview
Provides care homes, healthcare facilities and services, and shared living solutions in France, Germany, Benelux, Italy, Spain, and the United Kingdom. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 1/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
CLARI Community Fair Values
Create NarrativeSee what 16 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Clariane SE Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €4.06 |
| 52 Week High | €5.51 |
| 52 Week Low | €3.27 |
| Beta | 0.81 |
| 1 Month Change | -4.65% |
| 3 Month Change | 7.12% |
| 1 Year Change | -10.34% |
| 3 Year Change | -44.38% |
| 5 Year Change | -86.77% |
| Change since IPO | -88.82% |
Recent News & Updates
Narrative Update • Jun 03
CLARI: Brand Strength And Margin Focus Will Support Future Re Rating
Analysts have adjusted their price target on Clariane to €5.10. This reflects updated assumptions for discount rate, revenue growth, profit margin and future P/E, and broadly aligns with a more constructive stance on the stock in recent research.
Narrative Update • May 01
CLARI: Softer Demand And Margin Risks Will Pressure Elevated Future P/E
Analysts have maintained their fair value estimate for Clariane at €3.10, while refining assumptions around the discount rate, revenue growth and margins after recent Street research reduced price targets due to softer near-term demand and margin pressure, yet still emphasized the company’s longer-term brand strength. Analyst Commentary Recent Street research around Clarus points to a more cautious tone that readers may want to keep in mind when comparing fair value estimates to current trading levels.Narrative Update • Apr 17
CLARI: Brand Strength And Margin Efficiency Will Support Future Upside Potential
Analysts have trimmed their price target on Clariane by €1, reflecting recent Street research that points to softer near term expectations while still highlighting the company’s brand assets and potential for margin improvement. Analyst Commentary Recent Street research on related names points to a mixed setup, with price targets trimmed following Q4 results that fell short of expectations and highlighted softer demand and margin pressure.Recent updates
Narrative Update • Jun 03
CLARI: Brand Strength And Margin Focus Will Support Future Re Rating
Analysts have adjusted their price target on Clariane to €5.10. This reflects updated assumptions for discount rate, revenue growth, profit margin and future P/E, and broadly aligns with a more constructive stance on the stock in recent research.Narrative Update • May 01
CLARI: Softer Demand And Margin Risks Will Pressure Elevated Future P/E
Analysts have maintained their fair value estimate for Clariane at €3.10, while refining assumptions around the discount rate, revenue growth and margins after recent Street research reduced price targets due to softer near-term demand and margin pressure, yet still emphasized the company’s longer-term brand strength. Analyst Commentary Recent Street research around Clarus points to a more cautious tone that readers may want to keep in mind when comparing fair value estimates to current trading levels.Narrative Update • Apr 17
CLARI: Brand Strength And Margin Efficiency Will Support Future Upside Potential
Analysts have trimmed their price target on Clariane by €1, reflecting recent Street research that points to softer near term expectations while still highlighting the company’s brand assets and potential for margin improvement. Analyst Commentary Recent Street research on related names points to a mixed setup, with price targets trimmed following Q4 results that fell short of expectations and highlighted softer demand and margin pressure.Narrative Update • Apr 02
CLARI: Higher Margin Focus And Steady Risk Profile Will Support Upside
Analysts have trimmed their fair value estimate for Clariane to €5.10 from €5.20, reflecting slightly softer assumed revenue growth, a modestly higher profit margin outlook, and a lower future P/E multiple. Analyst Commentary Bullish analysts continue to see room for value in Clariane despite the recent trim to fair value, with attention on execution against revenue and margin assumptions rather than broad multiple expansion.Narrative Update • Mar 19
CLARI: Softer Revenue And Margin Pressure Will Strain Elevated Future P/E
Analysts have lowered their price target on Clariane from €4.00 to €3.10, citing softer revenue growth assumptions, lower expected profit margins, and a higher discount rate. Together, these factors point to a richer future P/E multiple of about 93x.
Narrative Update • Mar 05
CLARI: Lower Discount Rate And Margin Outlook Will Support Bullish Momentum
Analysts have nudged their price target on Clariane slightly higher to €4.53 from €4.49, reflecting updated assumptions around discount rates, revenue growth, profit margins and future P/E levels. Valuation Changes Fair Value: updated slightly higher from €4.49 to €4.53.Narrative Update • Feb 18
CLARI: Stable Assumptions And Lower P/E Multiple Will Support Bullish Momentum
Analysts have trimmed their 12 month price target for Clariane to €4.49. This reflects slightly adjusted assumptions on revenue growth, profit margins and future P/E expectations, while keeping the overall valuation framework unchanged.Narrative Update • Feb 03
CLARI: Stable Fair Value And Slight Margin Improvement Will Support Upside
Analysts have trimmed their price target on Clariane to €5.20, citing only slight adjustments to expected revenue growth, profit margins, and future P/E assumptions. Their overall valuation framework remains broadly unchanged.Narrative Update • Jan 20
CLARI: Earnings Guidance Confirmation Will Support Bullish Momentum Through 2025 Targets
Analysts have trimmed their price target for Clariane to reflect a fair value move from €4.72 to about €4.49, citing slightly adjusted revenue growth assumptions, a marginally higher profit margin outlook, and a lower future P/E multiple. What's in the News Clariane confirmed its group earnings guidance for 2025, repeating its targets rather than updating them (Key Developments).Narrative Update • Jan 06
CLARI: Confirmed 2025 Guidance And Higher Future P/E Will Support Upside
Analysts have adjusted their price target on Clariane to reflect an unchanged fair value of €5.20, revised revenue growth and profit margin assumptions, and a higher future P/E of 16.77x. What's in the News Clariane SE confirmed its group earnings guidance for 2025, giving investors a clearer view of management expectations for the year (Key Developments).Narrative Update • Dec 20
CLARI Will Benefit From Confirmed 2025 Guidance And Revenue Visibility
Narrative Update on Clariane Analysts have trimmed their price target on Clariane from €6.80 to €5.20, citing lower expected revenue growth, compressed profit margins, and a higher implied future valuation multiple that together point to a more challenging earnings outlook. What's in the News Clariane SE confirmed its group earnings guidance for 2025, maintaining an organic revenue growth target of around 5 percent (company guidance) The reaffirmed 2025 target indicates that management remains confident in demand resilience and the companys ability to execute its strategic plan despite margin pressures (company guidance) Stable forward guidance provides greater visibility for investors, which may reduce uncertainty around Clarianes medium term growth trajectory (company guidance) Valuation Changes Fair Value: reduced significantly from €6.80 to €5.20, implying a more cautious assessment of upside potential.Narrative Update • Dec 06
CLARI: Earnings Guidance Confirmation Will Support Bullish Momentum Into 2025
Narrative Update on Clariane Analysts have marginally increased their price target on Clariane to approximately €4.72, reflecting slightly stronger expectations for revenue growth and profit margins, while maintaining a broadly unchanged valuation framework. What's in the News Clariane SE confirmed its group earnings guidance for 2025, reiterating confidence in its financial trajectory despite sector headwinds (company guidance).Narrative Update • Nov 22
CLARI: Earnings Guidance Confirmation Will Support Bullish Momentum Into 2025
Clariane’s analyst price target has been revised downward from €5.16 to €4.72, as analysts cite a combination of slower revenue growth and weaker profit margins to support this updated outlook. What's in the News Clariane SE has confirmed its group earnings guidance for the year 2025 (Key Developments) The company reiterated its organic revenue growth target of approximately 5% for 2025 (Key Developments) Valuation Changes The consensus analyst price target has fallen from €5.16 to €4.72, reflecting a revised outlook.Analysis Article • Nov 08
The Price Is Right For Clariane SE (EPA:CLARI) Even After Diving 26%
The Clariane SE ( EPA:CLARI ) share price has fared very poorly over the last month, falling by a substantial 26...Analysis Article • Oct 12
These 4 Measures Indicate That Clariane (EPA:CLARI) Is Using Debt Extensively
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Narrative Update • Aug 07
Aging Europe And Digital Adoption Will Advance Long Term Care
Clariane’s fair value has been revised upward as improving net profit margin outweighed the impact of a higher discount rate, resulting in the consensus price target rising from €4.91 to €5.16. What's in the News Clariane SE expects organic sales growth of around 5% for 2025, supported by strong momentum in France and Germany, with ramp-up contributions in the Netherlands and Spain.Analysis Article • Jun 22
Revenues Tell The Story For Clariane SE (EPA:CLARI)
There wouldn't be many who think Clariane SE's ( EPA:CLARI ) price-to-sales (or "P/S") ratio of 0.3x is worth a mention...New Narrative • May 05
Refinancing And French Pricing Will Pressure Margins But Build Resilience
Ongoing disposal plan and deleveraging efforts may limit opportunistic growth and reduce future revenue streams.Analysis Article • Apr 03
Does Clariane (EPA:CLARI) Have A Healthy Balance Sheet?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analysis Article • Mar 03
Why Investors Shouldn't Be Surprised By Clariane SE's (EPA:CLARI) 70% Share Price Surge
Despite an already strong run, Clariane SE ( EPA:CLARI ) shares have been powering on, with a gain of 70% in the last...Analysis Article • Dec 28
Clariane (EPA:CLARI) Has A Somewhat Strained Balance Sheet
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analysis Article • Nov 05
Revenues Tell The Story For Clariane SE (EPA:CLARI) As Its Stock Soars 26%
Clariane SE ( EPA:CLARI ) shareholders would be excited to see that the share price has had a great month, posting a...Analysis Article • Sep 13
Here's Why Clariane (EPA:CLARI) Has A Meaningful Debt Burden
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analysis Article • Aug 06
Clariane SE's (EPA:CLARI) 26% Cheaper Price Remains In Tune With Revenues
Unfortunately for some shareholders, the Clariane SE ( EPA:CLARI ) share price has dived 26% in the last thirty days...Analysis Article • Jun 04
Here's Why It's Unlikely That Clariane SE's (EPA:CLARI) CEO Will See A Pay Rise This Year
Key Insights Clariane to hold its Annual General Meeting on 10th of June Salary of €520.0k is part of CEO Sophie...Analysis Article • May 22
Clariane SE (EPA:CLARI) Shares Could Be 33% Below Their Intrinsic Value Estimate
Key Insights Clariane's estimated fair value is €7.05 based on Dividend Discount Model Current share price of €4.75...Analysis Article • May 22
Market Participants Recognise Clariane SE's (EPA:CLARI) Revenues Pushing Shares 187% Higher
The Clariane SE ( EPA:CLARI ) share price has done very well over the last month, posting an excellent gain of 187...Analysis Article • Apr 28
Clariane (EPA:CLARI) Takes On Some Risk With Its Use Of Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analysis Article • Dec 06
Is It Too Late To Consider Buying Clariane SE (EPA:CLARI)?
Clariane SE ( EPA:CLARI ), might not be a large cap stock, but it received a lot of attention from a substantial price...Analysis Article • Oct 31
These 4 Measures Indicate That Clariane (EPA:CLARI) Is Using Debt Extensively
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Analysis Article • Sep 21
Calculating The Fair Value Of Clariane SE (EPA:CLARI)
Key Insights The projected fair value for Clariane is €6.91 based on Dividend Discount Model Current share price of...Analysis Article • Jul 29
What Is Clariane SE's (EPA:CLARI) Share Price Doing?
While Clariane SE ( EPA:CLARI ) might not be the most widely known stock at the moment, it saw a decent share price...Analysis Article • Apr 04
At €6.98, Is It Time To Put Korian (EPA:KORI) On Your Watch List?
Korian ( EPA:KORI ), might not be a large cap stock, but it received a lot of attention from a substantial price...Analysis Article • Mar 16
These 4 Measures Indicate That Korian (EPA:KORI) Is Using Debt Extensively
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analysis Article • Jan 16
A Look At The Fair Value Of Korian (EPA:KORI)
Key Insights Korian's estimated fair value is €9.9 based on Dividend Discount Model Current share price of €10.3...Shareholder Returns
| CLARI | FR Healthcare | FR Market | |
|---|---|---|---|
| 7D | 0.2% | -0.8% | 2.7% |
| 1Y | -10.3% | 5.9% | 6.3% |
Return vs Industry: CLARI underperformed the French Healthcare industry which returned 8.3% over the past year.
Return vs Market: CLARI underperformed the French Market which returned 4.8% over the past year.
Price Volatility
| CLARI volatility | |
|---|---|
| CLARI Average Weekly Movement | 4.6% |
| Healthcare Industry Average Movement | 4.5% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in FR Market | 11.2% |
| 10% least volatile stocks in FR Market | 2.7% |
Stable Share Price: CLARI has not had significant price volatility in the past 3 months compared to the French market.
Volatility Over Time: CLARI's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 70,685 | Sophie Boissard | www.clariane.com |
Clariane SE provides care homes, healthcare facilities and services, and shared living solutions in France, Germany, Benelux, Italy, Spain, and the United Kingdom. It operates long-term care and short stay nursing homes. The company also provides inpatient and outpatient services, full-time hospitalization, day hospitalization, and outpatient care, and operates post-acute and rehabilitation care clinics, mental healthcare clinics, and medicine-surgery-obstetrics facilities.
Clariane SE Fundamentals Summary
| CLARI fundamental statistics | |
|---|---|
| Market cap | €1.45b |
| Earnings (TTM) | €1.60m |
| Revenue (TTM) | €5.31b |
907.5x
P/E Ratio0.3x
P/S RatioIs CLARI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CLARI income statement (TTM) | |
|---|---|
| Revenue | €5.31b |
| Cost of Revenue | €3.66b |
| Gross Profit | €1.65b |
| Other Expenses | €1.65b |
| Earnings | €1.60m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
Jul 29, 2026
| Earnings per share (EPS) | 0.0045 |
| Gross Margin | 31.16% |
| Net Profit Margin | 0.03% |
| Debt/Equity Ratio | 98.4% |
How did CLARI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/16 12:24 |
| End of Day Share Price | 2026/06/16 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Clariane SE is covered by 14 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Fraser Donlon | Berenberg |
| Aleksander Peterc | Bernstein |
| Laurent Gelebart | BNP Paribas |